Ajanta Pharma Ltd logo

Ajanta Pharma Ltd

AJANTPHARM NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹47,208 Cr
Volatility
High Risk
P/E Ratio
40.82
EBITDA
₹1,567 Cr
Return on Equity
23.33%
Debt to Equity
0.06
Book Value
₹362.28
EPS
₹67.81
52W High
₹3,738
52W Low
₹2,329.9

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Ajanta Pharma Ltd insights

59 extracted metrics + investor summaries across FY12–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
  • Company has been maintaining a healthy dividend payout of 50.1%

Weaknesses

2
  • Stock is trading at 10.3 times its book value
  • Promoter holding has decreased over last quarter: -2.76%

Growth Rate

Revenue Growth
18.60% ↗
Net Income Growth
14.73% ↘
Cash Flow Change
-54.27% ↘
ROE
-3.91% ↘
ROCE
-2.32% ↘
EBITDA Margin (Avg.)
-2.42% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Ajanta Pharma is a debt-free, mid-cap pharmaceutical company with a market cap of ₹45,187 Cr, trading at a PE of 39x and delivering consistent ROE of 25-27%. The company has compounded sales at 13-14% over 3-5 years while profit growth has accelerated to 22-24% in recent periods, though the stock trades at an elevated 9.78x book value.

Bull Case 7
  • Company is virtually debt-free, providing financial flexibility and minimal interest burden on earnings
  • Consistent ROE track record of 23-27% across 3, 5, and 10-year periods, with last year's ROE at 27% indicating improving capital efficiency
  • TTM sales growth of 20% represents a meaningful acceleration over the 3-year CAGR of 13% and 5-year CAGR of 14%
  • Compounded profit growth of 24% over 3 years outpaces revenue growth of 13%, signalling operating leverage and margin expansion
  • Healthy dividend payout ratio of 50.1% with a current yield of 0.9%, demonstrating shareholder-friendly capital allocation
  • Stock price CAGR of 33% over 1 year and 27% over 3 years reflects strong market recognition of operational performance
  • 10-year compounded sales CAGR of 12% and profit CAGR of 10% demonstrate long-term business durability across market cycles
Bear Case 7
  • PE ratio of 39x is significantly above the broader pharma sector average, leaving limited margin of safety if growth slows
  • Price-to-book ratio of 9.78x is elevated and implies very high expectations for future returns are already priced in
  • Promoter holding decreased by 2.76% in the last quarter, which may signal reduced insider confidence or diversification motives
  • 5-year compounded profit CAGR of 12% is materially lower than the 3-year figure of 24%, suggesting recent profit acceleration may not be structurally sustained
  • 10-year profit CAGR of only 10% versus 10-year sales CAGR of 12% indicates historically modest margin improvement over longer periods
  • Dividend yield of 0.9% offers limited income protection relative to current risk-free rates above 7%
  • Stock price 10-year CAGR of 11% trails the more recent 3-year CAGR of 27%, highlighting periods of significant underperformance in the past

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 17h ago
Positives 2
  • Q1FY27 profit surges 31% YoY Jul 31

    Consolidated net profit rose 30.9% YoY to ₹334.22 crore for Q1FY27, with revenue up 24.8% to ₹1,625.96 crore driven by US Generic and Africa Institutional segments.

  • ₹32 interim dividend declared Jul 30

    Board declared ₹32 per share interim dividend with Aug 5 record date, signaling confidence after strong Q1 earnings.

Neutral 3
  • Promoter releases excess pledge Aug 14

    Ravi Agrawal Trust released pledge on 54,796 shares citing excess pledge across lenders including Bajaj Finance and Infina Finance, reducing overall encumbrance.

  • Aug investor meetings scheduled Aug 5

    Ajanta Pharma announced analyst and institutional investor meetings in Singapore, Hong Kong, and Mumbai during August 2026.

  • Q1FY27 earnings call held Jul 30

    Earnings call audio for quarter ended June 30, 2026 was released on July 30 with written transcript to follow.

TL;DR: Ajanta Pharma delivered a strong Q1FY27 with 31% profit growth and 25% revenue expansion, supported by US Generics and Africa Institutional business. No material headwinds are visible in recent news flow. The promoter reducing pledge and a healthy ₹32 dividend reinforce confidence. The trend is clearly improving with robust top-line and bottom-line momentum heading into Q2.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,021
1,028
1,105
1,054
1,145
1,187
1,146
1,170
1,303
1,354
1,375
1,422
1,626
Expenses
750
738
791
776
815
875
825
873
951
1,026
993
1,088
1,202
Operating Profit
271
291
314
278
330
311
321
297
351
328
382
333
424
OPM %
27%
28%
28%
26%
29%
26%
28%
25%
27%
24%
28%
23%
26%
Other Income
32
21
14
36
26
19
30
18
26
59
25
61
71
Interest
1
2
2
2
1
6
8
6
5
3
5
2
3
Depreciation
33
34
34
34
34
34
36
40
41
43
44
45
44
PBT
269
276
291
278
322
290
307
269
331
341
359
347
447
Tax %
23%
29%
28%
27%
24%
25%
24%
16%
23%
24%
24%
23%
25%
Net Profit
208
195
210
203
246
216
233
225
255
260
274
267
334
EPS in Rs
16.24
15.24
16.39
15.82
19.68
17.33
18.64
18.03
20.44
20.83
21.91
21.35
26.75
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,474
1,749
1,983
2,126
2,055
2,588
2,890
3,341
3,743
4,209
4,648
5,453
5,776
Expenses
968
1,155
1,292
1,467
1,489
1,904
1,889
2,408
2,934
3,037
3,379
3,953
4,309
Operating Profit
505
594
691
658
567
683
1,001
933
808
1,172
1,269
1,500
1,467
OPM %
34%
34%
35%
31%
28%
26%
35%
28%
22%
28%
27%
28%
25%
Other Income
8
14
20
24
21
88
24
112
74
85
85
67
217
Interest
6
5
1
0
1
12
8
10
6
7
21
16
14
Depreciation
52
44
61
60
72
96
116
125
131
135
144
173
176
PBT
456
559
648
623
514
664
900
909
745
1,114
1,189
1,378
1,493
Tax %
32%
26%
22%
25%
25%
30%
27%
22%
21%
27%
23%
23%
—
Net Profit
310
416
507
469
387
468
654
713
588
816
920
1,056
1,135
EPS in Rs
23.47
31.49
38.4
35.5
29.56
35.73
50.38
55.63
45.89
63.7
73.68
84.52
90.84
Div. Payout %
17%
17%
23%
0%
20%
24%
13%
11%
15%
79%
38%
33%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
18
18
18
18
18
18
17
17
25
25
25
25
Reserves
823
1,173
1,550
2,024
2,228
2,581
2,978
3,247
3,363
3,542
3,765
4,502
Borrowings
72
81
1
2
36
75
31
25
36
35
47
260
Other Liabilities
233
207
254
383
383
619
702
711
1,159
927
1,067
1,250
Total Liabilities
1,146
1,479
1,823
2,426
2,664
3,293
3,729
4,000
4,582
4,530
4,904
6,037
Fixed Assets
288
451
589
1,053
1,178
1,472
1,541
1,512
1,496
1,479
1,762
1,867
CWIP
170
240
339
61
262
132
108
153
209
256
176
258
Investments
60
86
182
190
78
79
176
147
535
349
464
588
Other Assets
629
703
713
1,122
1,147
1,610
1,904
2,188
2,341
2,446
2,502
3,324
Total Assets
1,146
1,479
1,823
2,426
2,664
3,293
3,729
4,000
4,582
4,530
4,904
6,037
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
279
326
609
281
375
457
576
562
792
785
1,157
529
Investing
-158
-209
-383
-256
-223
-224
-282
-74
-560
65
-377
-429
Financing
-105
-117
-202
0
-147
-129
-318
-460
-108
-1,051
-733
-168
Net Cash Flow
16
0
24
25
4
104
-24
28
124
-201
47
-68
Free Cash Flow
176
29
313
19
32
228
417
431
618
646
840
169
CFO/OP
84
82
110
64
87
89
81
86
117
94
117
59
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
78
59
79
82
109
93
111
103
108
93
124
Inventory Days
159
180
186
315
415
276
434
347
283
283
308
289
Days Payable
109
128
157
224
214
202
212
143
147
159
155
168
Cash Conversion Cycle
114
130
88
170
282
184
315
315
240
233
246
246
Working Capital Days
56
78
65
103
113
108
126
140
83
119
97
111
ROCE %
57%
52%
46%
34%
24%
27%
32%
29%
23%
32%
32%
35%

Shareholding Pattern

As of Jun 2026
Promoters 63.48%
DIIs 21.80%
FIIs 7.68%
Public 6.27%
Others 0.76%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Apr 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
70.34%
70.34%
70.34%
70.34%
70.48%
70.48%
70.48%
66.11%
66.11%
66.21%
66.21%
66.21%
66.21%
66.21%
66.27%
66.26%
66.26%
66.26%
66.26%
66.25%
66.25%
66.25%
63.48%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
8.54%
8.36%
9.11%
9.26%
8.86%
8.86%
8.53%
7.98%
8.26%
7.68%
DIIs
10.88%
11.04%
11.51%
11.55%
11.61%
11.92%
12.15%
15.82%
15.98%
16.02%
14.70%
14.91%
16.01%
17.49%
17.41%
17.10%
17.02%
17.48%
17.50%
17.90%
18.58%
18.37%
21.80%
Government
0.76%
0.43%
0.43%
0.45%
0.45%
0.45%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.00%
Public
7.64%
7.42%
7.45%
7.29%
7.33%
7.45%
7.31%
7.17%
7.10%
6.94%
6.92%
7.21%
7.07%
6.91%
7.08%
6.71%
6.67%
6.63%
6.59%
6.53%
6.44%
6.35%
6.27%
Others
10.37%
10.76%
10.26%
10.37%
10.13%
9.70%
10.06%
10.90%
10.82%
10.82%
12.16%
11.67%
10.70%
0.84%
0.86%
0.80%
0.79%
0.76%
0.79%
0.79%
0.76%
0.77%
0.76%
No. of Shareholders
44,881
45,664
52,263
57,897
60,759
64,445
62,048
59,798
83,549
56,939
54,874
56,277
54,351
55,488
70,316
64,315
66,896
70,827
68,882
67,785
65,409
67,955
65,296

Documents

Frequently Asked Questions about Ajanta Pharma Ltd

What does Ajanta Pharma Ltd do?
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
Where is Ajanta Pharma Ltd (AJANTPHARM) listed?
Ajanta Pharma Ltd is listed on the Indian stock exchanges. It is listed on NSE: AJANTPHARM and BSE: 532331. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Ajanta Pharma Ltd belong to?
Ajanta Pharma Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Ajanta Pharma Ltd?
Ajanta Pharma Ltd has a market capitalisation of approximately ₹47208.17 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Ajanta Pharma Ltd?
The Price-to-Earnings (PE) ratio of Ajanta Pharma Ltd is 40.82. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Ajanta Pharma Ltd?
Over the past 52 weeks, Ajanta Pharma Ltd has traded between a low of ₹2,329.9 and a high of ₹3,738. This range helps investors understand the stock's price volatility and recent trading levels.
Does Ajanta Pharma Ltd pay dividends?
Yes, Ajanta Pharma Ltd has a dividend yield of 0.86%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Ajanta Pharma Ltd?
Ajanta Pharma Ltd has a Return on Equity (ROE) of 23.33%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Ajanta Pharma Ltd on Tapetide?
On Tapetide, you can view Ajanta Pharma Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

Website ajantapharma.com
CEO Mr. Yogesh Mannalal Agrawal M.B.A
Employees 9,628
Listed 2000-05-29
Face Value ₹ 2
Issued Size 12,49,35,624

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List